Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.86 USD | -4.73% | -11.98% | +4.41% |
Financials (USD)
Sales 2024 * | 239K | Sales 2025 * | 8.8M | Capitalization | 171M |
---|---|---|---|---|---|
Net income 2024 * | -119M | Net income 2025 * | -147M | EV / Sales 2024 * | 94.3 x |
Net cash position 2024 * | 149M | Net cash position 2025 * | 136M | EV / Sales 2025 * | 4.06 x |
P/E ratio 2024 * |
-1.32
x | P/E ratio 2025 * |
-1.44
x | Employees | 121 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.21% |
Latest transcript on Adverum Biotechnologies, Inc.
1 day | -4.73% | ||
1 week | -11.98% | ||
Current month | -19.14% | ||
1 month | -30.69% | ||
3 months | -60.10% | ||
6 months | -8.60% | ||
Current year | +4.41% |
Managers | Title | Age | Since |
---|---|---|---|
Laurent Fischer
CEO | Chief Executive Officer | 60 | 20-06-14 |
Linda Rubinstein
DFI | Director of Finance/CFO | 58 | 22-12-11 |
Bill Tan
CTO | Chief Tech/Sci/R&D Officer | - | 21-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Scott Whitcup
BRD | Director/Board Member | 64 | 20-04-15 |
Clarence Machado
CHM | Chairman | 60 | 17-03-13 |
Laurent Fischer
CEO | Chief Executive Officer | 60 | 20-06-14 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-21 | 7.86 | -4.73% | 807,988 |
24-05-20 | 8.25 | +2.61% | 572,719 |
24-05-17 | 8.04 | -2.55% | 1,794,585 |
24-05-16 | 8.25 | -5.71% | 353,791 |
24-05-15 | 8.75 | -2.02% | 252,881 |
Delayed Quote Nasdaq, May 21, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.41% | 171M | |
+8.63% | 115B | |
+13.17% | 107B | |
-12.76% | 22.31B | |
-3.99% | 21.6B | |
-7.19% | 18.23B | |
-39.93% | 17.62B | |
+6.67% | 14.26B | |
+33.90% | 12.37B | |
-28.60% | 8.28B |
- Stock Market
- Equities
- ADVM Stock